Reporting Obligations
Acute flaccid paralysis (AFP) is designated as a disease of public health significance and is reportable under the Ontario Health Protection and Promotion Act. Report suspect and confirmed cases within one business day to the local Health Unit.
Epidemiology
Aetiologic Agent:
AFP is a clinical syndrome, typically characterized by rapid onset
weakness, which may include respiratory and bulbar weakness. AFP is a broad
clinical syndrome with an array of diagnostic possibilities, and may be the
result of infectious or non-infectious agents. Surveillance is conducted in
an attempt to identify cases of AFP and to investigate all reported cases
for evidence to rule out poliomyelitis (polio), which is essential for
maintaining Canada’s polio-free status.
AFP may be caused by a number of agents. The immune- mediated condition
Guillain-Barré Syndrome (GBS) is the most common cause of AFP in Canada.
The causes of AFP, some of which lead to GBS, include, but are not limited
to, enteroviruses (including poliovirus), adenoviruses, acute West Nile
virus infection, Campylobacter spp., transverse myelitis,
peripheral neuropathy, acute non-bacterial meningitis, brain abscess, China
syndrome, post-polio sequelae, tick paralysis, myasthenia gravis, porphyria
and botulism. Poliomyelitis must be distinguished from other paralytic conditions by isolation of poliovirus
from stool.
Clinical Presentation:
Acute onset of focal weakness or paralysis, characterized as flaccid
without other obvious cases (e.g., trauma), in children less than 15 years
old.
The most characteristic feature of AFP associated with paralytic polio is
its asymmetric distribution (not affecting both sides equally), which
affects some muscle groups while sparing others, with fever present at
onset. The most typical pattern is involvement of one leg only, or on arm,
although this occurs less often. It is less common for both legs or both
arms to be affected.
AFP due to Guillain-Barré Syndrome (GBS) may present as symmetrical
paralysis and may progress for up to 10 days.
Modes of transmission:
Depends on causative agent.
Incubation Period:
Depends on the causative agent.
Period of Communicability:
Varies, depending on causative agent.
Risk Factors/Susceptibility
Depends on causative agent.
Diagnosis & Laboratory Testing
Clinically confirmed case: Acute onset of focal weakness or paralysis
characterized as flaccid (reduced tone) without other obvious cause (e.g.
trauma) in children <15 years old. Cases of Guillain-Barré Syndrome
(GBS) should be included as cases of Acute Flaccid Paralysis (AFP).
Transient weakness (e.g. post-ictal weakness) should not be reported.
AFP is a syndrome which can be caused by a number of pathogens. The
following laboratory testing (of stool, respiratory secretions,
cerebrospinal fluid (CSF) and other appropriate clinical specimens) is used
to rule out poliomyelitis and/or determine pathogens causing AFP:
- Stool samples - collection of two stool samples within two weeks (up to
six weeks) after the onset of paralysis for viral studies and campylobacter
- Serology testing is not recommended for diagnosis of polio or non-polio
enterovirus infection
- Depending on the clinical presentation, a nasopharyngeal swab, and/or
cerebrospinal fluid (CSF) may be collected to assist with the investigation
- Neurologic investigations, as appropriate, should take place
(electromyography, nerve conduction studies, MRI, CT)
Please see additional information (Quick Links) from Public Health Ontario
- AFP/EV-D68 Testing Requisition;
General Test Requisition ;
and Case Report Form
Treatment & Case Management
Treatment is under the direction of the attending health care provider.
Routine Practices are recommended for hospitalized cases and additional
precautions would depend on the causative organism.
Immediate case investigation and specimen collection is essential by Public
Health staff to rule out polio as a source of infection, maintain Canada’s
polio-free certification status, and determine the source of infection.
Patient Information
Additional Resources
1.
PHAC. “Poliomyelitis (Polio) Vaccine- Preventable Diseases,December 4, 2013.”
2.
Public Health Ontario. “Enterovirus D68 (includes AFP Testing and
Reporting).
”
3. Heymann, D.L. Control of Communicable Disease Manual (21th Ed.). Washington, American Public Health Association, 2022.
References
1. Ministry of Health, Infectious Diseases Protocol - Ontario Public Health Standards, 2022.